Baricitinib represents a genuinely different product category from the injectable biologics that make up most of our immunotherapy catalogue — it's an oral JAK-inhibitor tablet, which means no cold-chain logistics, no infusion-center requirement, and no self-injection training, making it a meaningfully easier product for distributors serving markets with limited cold-chain infrastructure to bring to patients.
- Approved indications: Rheumatoid arthritis, atopic dermatitis, alopecia areata
- Mechanism: Inhibits JAK1 and JAK2 enzymes, blocking intracellular signaling pathways that drive inflammatory disease activity
- Administration: Oral tablet, once daily — no infusion, injection, or refrigerated storage required
- Logistics advantage: Room-temperature stable, significantly reducing shipping cost and complexity compared to the biologics in our catalogue
- Boxed-warning class risk: As with all JAK-inhibitors, increased risk of serious infections, malignancy, major cardiovascular events, and blood clots — particularly relevant in patients over 50 with existing cardiovascular risk factors
- Screening requirement: Active tuberculosis and hepatitis must be ruled out before starting treatment
- Pregnancy: Contraindicated
- Monitoring: Regular blood count and lipid panel monitoring recommended throughout treatment
- Certification: WHO-GMP tablet manufacturing
- Batch-specific testing: Dissolution and bioequivalence testing per batch
- Non-cold-chain advantage: As an oral product, manufacturing and quality-control focus centers on tablet uniformity and dissolution profile rather than the biologic-stability concerns that dominate our injectable product line
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics — no cold chain required, meaningfully lowering total shipping cost for distributors compared to injectable biologics
- Coverage: Global export markets, especially relevant for distributors serving regions with limited cold-chain infrastructure
- Tracking: Full shipment tracking included
- Institutional buyers: Pharmacy and hospital distributor support
- Market fit: Particularly suitable for regions where cold-chain logistics for biologics is a genuine barrier to consistent supply
- Unregistered markets: Named-patient supply pathway available
What is Baricitinib used for?
Treats rheumatoid arthritis, atopic dermatitis, and alopecia areata.
Get Baricitinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it need cold chain shipping?
No, it's an oral tablet stable at room temperature, unlike most biologics in this category.
Is it safe for older patients?
Requires caution — JAK-inhibitors carry a higher risk profile in patients over 50 with cardiovascular risk factors.
Who supplies Baricitinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
